Cytomegalovirus infection after bone marrow transplantation in children

Elio Castagnola, Barbara Cappelli, Daniela Erba, Anna Rabagliati, Edoardo Lanino, Giorgio Dini

Research output: Contribution to journalArticle

Abstract

Cytomegalovirus (CMV) is a well-known cause of disease occurring after bone marrow transplantation (BMT). The manifestations of CMV range from asymptomatic infection, defined as active CMV replication in the blood in the absence of clinical manifestations or organ failure abnormalities, to CMV disease, characterized by CMV infection with clinical symptoms or organ function abnormalities. Diagnostic procedures to assess the viral load have improved greatly with the increased use of antigenemia, CMV DNA, and immediate early-messenger RNA. Many conditions concur in determining the risk of developing CMV reactivation or disease after bone marrow transplant with serologic status of donor and recipient, type of bone marrow transplant, presence of graft-versus-host disease being the most studied. However, time and quality of immune reconstitution seems to be the pivotal factors. Pneumonia and gastrointestinal involvement are the most frequently documented clinical pictures with late-onset CMV reactivation or disease representing a new challenge. CMV prophylaxis or pre-emptive therapy adopted during the last few years in allogeneic BMT recipients has changed the natural history of the disease, reducing the risk of CMV disease, CMV-associated death, transplant-related mortality, and has prolonged the period at risk. Specific studies on children are lacking, however, the clinical pictures and features seems to be similar both in children and adults.

Original languageEnglish
Pages (from-to)416-422
Number of pages7
JournalHuman Immunology
Volume65
Issue number5
DOIs
Publication statusPublished - May 2004

Fingerprint

Cytomegalovirus Infections
Cytomegalovirus
Bone Marrow Transplantation
Transplants
Bone Marrow Diseases
Asymptomatic Infections
Homologous Transplantation
Graft vs Host Disease
Viral Load
Pneumonia
Bone Marrow
Tissue Donors
Messenger RNA
Mortality
DNA

Keywords

  • Bone marrow transplant
  • graft versus host disease
  • hemopoietic stem cell transplant
  • human cytomegalovirus
  • pre-emptive therapy
  • transplant-related mortality

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy

Cite this

Cytomegalovirus infection after bone marrow transplantation in children. / Castagnola, Elio; Cappelli, Barbara; Erba, Daniela; Rabagliati, Anna; Lanino, Edoardo; Dini, Giorgio.

In: Human Immunology, Vol. 65, No. 5, 05.2004, p. 416-422.

Research output: Contribution to journalArticle

Castagnola, Elio ; Cappelli, Barbara ; Erba, Daniela ; Rabagliati, Anna ; Lanino, Edoardo ; Dini, Giorgio. / Cytomegalovirus infection after bone marrow transplantation in children. In: Human Immunology. 2004 ; Vol. 65, No. 5. pp. 416-422.
@article{4ca2269e9b224348947bbca6453ed04e,
title = "Cytomegalovirus infection after bone marrow transplantation in children",
abstract = "Cytomegalovirus (CMV) is a well-known cause of disease occurring after bone marrow transplantation (BMT). The manifestations of CMV range from asymptomatic infection, defined as active CMV replication in the blood in the absence of clinical manifestations or organ failure abnormalities, to CMV disease, characterized by CMV infection with clinical symptoms or organ function abnormalities. Diagnostic procedures to assess the viral load have improved greatly with the increased use of antigenemia, CMV DNA, and immediate early-messenger RNA. Many conditions concur in determining the risk of developing CMV reactivation or disease after bone marrow transplant with serologic status of donor and recipient, type of bone marrow transplant, presence of graft-versus-host disease being the most studied. However, time and quality of immune reconstitution seems to be the pivotal factors. Pneumonia and gastrointestinal involvement are the most frequently documented clinical pictures with late-onset CMV reactivation or disease representing a new challenge. CMV prophylaxis or pre-emptive therapy adopted during the last few years in allogeneic BMT recipients has changed the natural history of the disease, reducing the risk of CMV disease, CMV-associated death, transplant-related mortality, and has prolonged the period at risk. Specific studies on children are lacking, however, the clinical pictures and features seems to be similar both in children and adults.",
keywords = "Bone marrow transplant, graft versus host disease, hemopoietic stem cell transplant, human cytomegalovirus, pre-emptive therapy, transplant-related mortality",
author = "Elio Castagnola and Barbara Cappelli and Daniela Erba and Anna Rabagliati and Edoardo Lanino and Giorgio Dini",
year = "2004",
month = "5",
doi = "10.1016/j.humimm.2004.02.013",
language = "English",
volume = "65",
pages = "416--422",
journal = "Human Immunology",
issn = "0198-8859",
publisher = "Elsevier Inc.",
number = "5",

}

TY - JOUR

T1 - Cytomegalovirus infection after bone marrow transplantation in children

AU - Castagnola, Elio

AU - Cappelli, Barbara

AU - Erba, Daniela

AU - Rabagliati, Anna

AU - Lanino, Edoardo

AU - Dini, Giorgio

PY - 2004/5

Y1 - 2004/5

N2 - Cytomegalovirus (CMV) is a well-known cause of disease occurring after bone marrow transplantation (BMT). The manifestations of CMV range from asymptomatic infection, defined as active CMV replication in the blood in the absence of clinical manifestations or organ failure abnormalities, to CMV disease, characterized by CMV infection with clinical symptoms or organ function abnormalities. Diagnostic procedures to assess the viral load have improved greatly with the increased use of antigenemia, CMV DNA, and immediate early-messenger RNA. Many conditions concur in determining the risk of developing CMV reactivation or disease after bone marrow transplant with serologic status of donor and recipient, type of bone marrow transplant, presence of graft-versus-host disease being the most studied. However, time and quality of immune reconstitution seems to be the pivotal factors. Pneumonia and gastrointestinal involvement are the most frequently documented clinical pictures with late-onset CMV reactivation or disease representing a new challenge. CMV prophylaxis or pre-emptive therapy adopted during the last few years in allogeneic BMT recipients has changed the natural history of the disease, reducing the risk of CMV disease, CMV-associated death, transplant-related mortality, and has prolonged the period at risk. Specific studies on children are lacking, however, the clinical pictures and features seems to be similar both in children and adults.

AB - Cytomegalovirus (CMV) is a well-known cause of disease occurring after bone marrow transplantation (BMT). The manifestations of CMV range from asymptomatic infection, defined as active CMV replication in the blood in the absence of clinical manifestations or organ failure abnormalities, to CMV disease, characterized by CMV infection with clinical symptoms or organ function abnormalities. Diagnostic procedures to assess the viral load have improved greatly with the increased use of antigenemia, CMV DNA, and immediate early-messenger RNA. Many conditions concur in determining the risk of developing CMV reactivation or disease after bone marrow transplant with serologic status of donor and recipient, type of bone marrow transplant, presence of graft-versus-host disease being the most studied. However, time and quality of immune reconstitution seems to be the pivotal factors. Pneumonia and gastrointestinal involvement are the most frequently documented clinical pictures with late-onset CMV reactivation or disease representing a new challenge. CMV prophylaxis or pre-emptive therapy adopted during the last few years in allogeneic BMT recipients has changed the natural history of the disease, reducing the risk of CMV disease, CMV-associated death, transplant-related mortality, and has prolonged the period at risk. Specific studies on children are lacking, however, the clinical pictures and features seems to be similar both in children and adults.

KW - Bone marrow transplant

KW - graft versus host disease

KW - hemopoietic stem cell transplant

KW - human cytomegalovirus

KW - pre-emptive therapy

KW - transplant-related mortality

UR - http://www.scopus.com/inward/record.url?scp=2542436679&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2542436679&partnerID=8YFLogxK

U2 - 10.1016/j.humimm.2004.02.013

DO - 10.1016/j.humimm.2004.02.013

M3 - Article

C2 - 15172440

AN - SCOPUS:2542436679

VL - 65

SP - 416

EP - 422

JO - Human Immunology

JF - Human Immunology

SN - 0198-8859

IS - 5

ER -